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Aim
We presently prescribe a variety of pharmacologic thera-
pies tailored to each patient’s characteristics. We studied
the current pharmacologic therapies at our outpatient
clinic in obese and non-obese children with type 2
diabetes mellitus (T2DM).
Methods
We treated 108, 80 obese and 28 non-obese, children
diagnosed as having T2DM. Among these patients, 26
obese and 23 non-obese children were assigned to phar-
macological therapies during the course of diabetes. The
frequency of progression to pharmacologic therapies was
significantly higher in non-obese than in obese patients
(82.1% vs. 32.5%, P<0.05). As to the indication for pharma-
cologic therapies, oral hypoglycemic drugs (OHD) and/or
insulin were started if the HbA1c value exceeded 7.0%
despite dietary and exercise management.
Results
1) For the 27 obese patients, metformin alone or in combi-
nation with an additional medication was frequently used,
i.e. 6 patients received metformin alone and 9 metformin
with additional OHD including an a-glucosidase inhibitor
and/or thiazolidinedione. Only 2 patients independently
received glimepiride as a sulfonylurea (SU). In addition,
9 patients were treated with insulin, using basal insulin
supported with OHD or biphagic pre-mixture insulin. 2)
On the other hand, the 23 non-obese patients were
frequently treated with insulin alone or in combination
with an additional medication followed by SU, i.e. 11
patients received insulin alone or with additional OHD,
and 9 used glimepiride alone or in combination with other
OHD. 3) New anti-diabetic drugs, a DPP-4 inhibitor and a
GLP-1 receptor agonist, seemed to exert positive effects
on glycemic control without occurrence of hypoglycemic
episodes in some patients regardless of the type of
diabetes. The non-obese patients tended to require phar-
macologic therapy, in particular insulin, at an earlier stage
of diabetes as compared to the obese patients. 4) Some
patients using insulin experienced mild hypoglycemia, but
no other significant adverse events were observed with any
of the medications.
Conclusion
We identified differences among pharmacologic therapies
between obese and non-obese children with T2DM. New
anti-diabetic drugs, an incretin mimetic and an enhancer,
seemed to be effective for some young patients, showing
efficacy similar to that in adult T2DM patients. These
results suggest that pharmacologic treatment strategies in
childhood T2DM should be tailored to individual patient
characteristics.
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